Menu

Pipeline Overview*

Pipeline Overview

Drug Planned
Indication
Pre-clinical Phase i/ii Phase iii NDA/MAA
GI & Inflammation
RHB-105 H. pylori infections
First Phase III study successfully met primary endpoint**
RHB-104 Crohn's disease
Phase III N. America study ongoing
Multiple sclerosis
Successfully completed Phase IIa study
RHB-106 Bowel cleanser
WW rights licensed to Salix Pharmaceuticals
BEKINDA®
(RHB-102)
Gastroenteritis & gastritis
Phase III U.S. study ongoing
Oncology - GI/Inflammation
IBS-D
Phase II U.S. study ongoing
Oncology support
antiemetic
European MAA in discussions with EU Member States***
YELIVA® (ABC294640) Multiple indications
Multiple Phase I/II studies initiated and planned
MESUPRON Solid tumors
Completed Phase II including pancreatic cancer****
RP101 Pancreatic cancer
Completed several clinical studies*****
Other
RIZAPORT®
(RHB-103)
Migraine
NDA filed - re-submission of NDA planned following Feb. 2014 CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE (OCT. 2015)
*Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** Based on top-line results;*** MAA - Marketing Authorization Application; **** Development plan for MESUPRON® under review; ***** RedHill acquired an option from RESprotect GmbH;